AI Meets Audit Powerhouse: Qualifyze Launches Quality Insights Platform to Help Global Pharma Manage Supplier Site Risk
FRANKFURT, Germany, May 29, 2025 /PRNewswire/ -- Qualifyze, already the global leader…
Exterro Cracks the Code for Partners Aiming to Drive Sustainable Revenue Growth in the Data Risk Management Market with Launch of ExPN – the Exterro Partner Network
ExPN members avoid the challenges of offering disparate point products with exclusive…
ESOC 2025: Combined oral contraceptives triple risk of cryptogenic stroke in young women, new study shows
HELSINKI, May 20, 2025 /PRNewswire/ -- New research presented today at the…
Madrigal Announces New Clinical Data Demonstrating Rezdiffra (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis
Late-breaking results from the open-label compensated MASH cirrhosis (F4c) arm of the…
New Data at DDW 2025 Further Demonstrates the TissueCypher Test’s Ability to Identify Patients at Increased Risk for Developing Esophageal Cancer
Additionally, an expert physician panel convened by EndoscopyNow will host a product…
New Study Shows Castle Biosciences DecisionDx-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity
Patients identified as low risk by DecisionDx-Melanoma had a 2.8% sentinel lymph…
New Data at AACR Annual Meeting Highlights Use of DecisionDx-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis
FRIENDSWOOD, Texas, April 25, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq:…
ACT21 Software Clinches Best Risk Implementation at IBSi Global FinTech Innovation Awards 2024
NOIDA, India, April 15, 2025 /PRNewswire/ -- ACT21 Software, a pioneering force…
Lockton launches Professional and Executive Risk, transforming its global financial lines business
KANSAS CITY, Mo., March 31, 2025 /PRNewswire/ -- Lockton, the world's largest…
Novartis appoints Karen Hale, Chief Legal and Compliance Officer, as Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer, steps down from the Executive Committee of Novartis
After nearly seven years as a member of the Executive Committee of…